Meetings - The ASCO Post

Though many case studies and anecdotal reports have touted the effectiveness of cannabinoids for cancer pain, in randomized studies, the areas in which they are effective are “fairly borderline,” acc...

Supportive Care

By Meg Barbor, MPH / August 25, 2018 / MASCC/ISOO 2018

Cannabinoids for Cancer Pain: Dangerous or Beneficial?

Cannabis has been used in health care for millennia, and its use has been well documented, albeit never definitively integrated into clinical practice. Recent societal changes and the increasing accep...

Supportive Care

By Meg Barbor, MPH / August 25, 2018 / MASCC/ISOO 2018

Therapeutic Applications for Cannabinoids in Oncology: The Debate Continues

In the early part of the 20th century, the U.S. government classified cannabis as a Schedule 1 drug: a dangerous substance with no medical value. For many years, that classification prevented systemat...

MASCC/ISOO 2018

Expert Point of View: Ian Olver, AM, MD, PhD

Cannabinoids for Cancer Pain: Dangerous or Beneficial?

Therapeutic Applications for Cannabinoids in Oncology: The Debate Continues

Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being